Live Earnings Conference Call: Catalyst Pharmaceuticals' Q1 2025 earnings call is happening now. NASDAQ:CPRX Catalyst Pharmaceuticals Q1 2025 Earnings Report $23.46 +0.40 (+1.73%) Closing price 05/7/2025 04:00 PM EasternExtended Trading$24.20 +0.74 (+3.15%) As of 08:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Live Call not available Live EventEarnings Conference CallCatalyst Pharmaceuticals Q1 202500:00 / 00:00Live Transcript Follow Audio Catalyst Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS $0.53Beat/MissN/AOne Year Ago EPSN/ACatalyst Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$130.86 millionBeat/MissN/AYoY Revenue GrowthN/ACatalyst Pharmaceuticals Announcement DetailsQuarterQ1 2025Date5/7/2025TimeAfter Market ClosesConference Call DateThursday, May 8, 2025Conference Call Time8:30AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Catalyst Pharmaceuticals Earnings HeadlinesCatalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business UpdateMay 7 at 4:14 PM | globenewswire.comIs Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?April 30, 2025 | finance.yahoo.comBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.May 8, 2025 | Golden Portfolio (Ad)Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025April 30, 2025 | globenewswire.comCatalyst Pharmaceuticals, Inc. (CPRX): Among Stocks with Consistent Growth to Buy NowApril 27, 2025 | msn.comCatalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025April 22, 2025 | globenewswire.comSee More Catalyst Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Catalyst Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Catalyst Pharmaceuticals and other key companies, straight to your email. Email Address About Catalyst PharmaceuticalsCatalyst Pharmaceuticals (NASDAQ:CPRX), a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.View Catalyst Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Disney Stock Jumps on Earnings—Is the Magic Sustainable?Archer Stock Eyes Q1 Earnings After UAE UpdatesFord Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx BoostPalantir Stock Drops Despite Stellar Earnings: What's Next?Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?Is Reddit Stock a Buy, Sell, or Hold After Earnings Release? Upcoming Earnings Enbridge (5/9/2025)Petróleo Brasileiro S.A. - Petrobras (5/12/2025)Simon Property Group (5/12/2025)JD.com (5/13/2025)NU (5/13/2025)Sony Group (5/13/2025)SEA (5/13/2025)Cisco Systems (5/14/2025)Toyota Motor (5/14/2025)NetEase (5/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
